Inotiv, Inc. Reports Q3 FY2025: Revenue Up 23.5% but Faces Ongoing Financial Challenges

Inotiv, Inc. (NASDAQ: NOTV) - Q3 FY2025 Review

Inotiv, Inc., a leading contract research organization specializing in drug discovery and development, reported its earnings for the nine months ending June 30, 2025. The company is navigating financial challenges and restructuring efforts, amidst mixed signals in its operational performance.

Key Financial Highlights:

• Total revenue for Q3 FY2025: $130.68 million, up 23.5% from $105.79 million in Q3 FY2024.
• Consolidated net loss for Q3 FY2025: $17.58 million, showing a 32.6% improvement from $26.09 million in the same quarter of the previous year.
• Service revenue reached $59.58 million for Q3 FY2025, up 9% from $54.36 million in the prior year.
• Product revenue increased to $71.10 million, a significant rise from $51.42 million.
• Operating loss for Q3 FY2025: $5.68 million, compared to a greater loss of $20.75 million in Q3 FY2024.
• Cash and cash equivalents decreased from $21.43 million (Sept 2024) to $6.22 million (June 2025).
• Weighted average shares outstanding increased from 25.99 million to 34.35 million year over year.

Positive Aspects:

• Increased revenue in both segments (RMS and DSA) suggests growing market demand.
• Successful completion of one property sale in connection with its ongoing restructuring efforts.
• Improvement in net loss percentage indicates better operational efficiency.
• Equity offering in December 2024 raised $27.52 million, enhancing liquidity.

Negative Aspects:

• Current liabilities rose significantly, notably accounts payable increasing to $45.37 million from $33.53 million.
• Total operating cash flows are negative; the company reported an operating cash flow deficit of $24.76 million for the nine months ending June 30, 2025.
• Overall debt, net of unamortized issuance costs, increased slightly to $396.54 million, up from $393.34 million.
• Ongoing litigation and regulatory scrutiny pose financial uncertainties, with a liabilities reserve of $10 million related to class action lawsuits.

Current Concerns:

• The company's negative cash flow and ongoing operational losses raise questions about their ability to comply with future financial covenants.
• Significant reliance on non-human primate (NHP) suppliers and potential legal disputes surrounding NHP importations increase operational risks.
• Management faces a material weakness in internal controls over financial reporting that has yet to be fully addressed.

Inotiv is attempting to stabilize its operations through site optimization and increasing NHP sales, alongside resolving pending legal challenges. However, its substantial debt load and the continuous need for capital raise questions about its long-term sustainability.